

Attorney Docket No. 1736/44160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Michael IBEA et al.

Serial No.: 08/702,114

Group Art Unit: 1811

Filed: August 23, 1996

Examiner: Anish Gupta


For: CHIMERIC FATTY BODY-PRO-GRF ANALOGS  
WITH INCREASED BIOLOGICAL POTENCY

TERMINAL DISCLAIMER UNDER 37 C.F.R. § 1.321

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

Sir:

Theratechnologies Inc. of Montreal, Quebec, Canada, represents that it is the Assignee of the entire right, title and interest in above-captioned patent application by virtue of an assignment from the inventors recorded in the U.S. Patent and Trademark Office on microfilm reel 8227, at frame 0671; that the undersigned, whose title is supplied below, is empowered to act in its behalf, and that to the best of the undersigned's knowledge and belief title is in Theratechnologies Inc., and Theratechnologies Inc. hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the above-captioned application, which would extend beyond the expiration date of the full statutory term defined in 35 U.S.C. §§ 154 to 156 and 173, of any patent granted on co-pending U.S. Patent Application Serial No. 08/702,113, filed August 23, 1996, and agrees that any patent granted on the above-captioned patent application shall be enforceable only for and during such period that the legal title to such patent shall be the same as the legal title to any patent granted on said co-pending U.S. Patent Application, this agreement to run with any patent granted on the above-captioned patent application and to be binding upon the grantee, its successors or assigns.



Terminal Disclaimer  
Serial No. 08/702,114  
Page 2

In making the above disclaimer, Theratechnologies Inc. does not disclaim the terminal part of any patent granted on the above-captioned application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §§ 154 to 156 and 173 of any patent granted on said co-pending patent application in the event that it later expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims cancelled by reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term.

A check in the amount of one hundred ten dollars (\$110.00) is submitted herewith in payment of the required disclaimer fee under 37 C.F.R. §1.20(d). This amount is believed correct, however, the Commissioner is hereby authorized to charge any deficiency, or credit any overpayment, to deposit account no. 05-1323 (Ref. Docket No. 1736/44160).

The undersigned hereby declares that all statements made herein of his own knowledge are true, and that all statements made on information and belief are believed to be true, and further, that these statements were made with the knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

THERATECHNOLOGIES INC.

March 25, 1998  
(date)

J. Saint-Denis  
Jacques M. Saint-Denis  
Vice President, Corporate Affairs